

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>NUFARM LIMITED</b>
<b>ABN</b>	<b>37 091 323 312</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>WILLIAM BRUCE GOODFELLOW</b>
<b>Date of last notice</b>	<b>11/11/16</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<b>Direct and Indirect</b>
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>Sulkem Company Ltd</b>
<b>Date of change</b>	<b>5/5/2017</b>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p><b>Direct:</b>  <b>113,140 Fully Paid Ordinary Shares</b></p> <p><b>Indirect:</b>  <b>Pacific Custodians Pty Ltd – 31,585 Fully Paid Ordinary Shares</b>  <b>MA Goodfellow – 13,000 Fully Paid Ordinary Shares and 100 NSS</b>  <b>St Kentigern Trust – 430,434 Fully Paid Ordinary Shares and 19,727 NSS</b>  <b>Sulkem Company Ltd – 129,120 Fully Paid Ordinary Shares</b>  <b>Auckland Medical Research Foundation – 26,558 NSS</b>  <b>Trustees of The Goodfellow Foundation – 33,854 Fully Paid Ordinary Shares and 1,338 NSS</b>  <b>Henry Berry Corporation Limited – 420,861 Fully Paid Ordinary Shares</b>  <b>700 NSS</b></p>
<p><b>Class</b></p>	<p><b>Ordinary Shares</b></p>
<p><b>Number acquired</b></p>	<p><b>Direct: 163 Fully Paid Ordinary Shares</b>  <b>Indirect: (Sulkem Company Ltd) 667 Fully Paid Ordinary Shares</b></p>
<p><b>Number disposed</b></p>	<p><b>NIL</b></p>
<p><b>Value/Consideration</b>  <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p><b>\$9.6881</b></p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<b>Direct:</b> <b>113,303 Fully Paid Ordinary Shares</b>  <b>Indirect:</b> <b>Pacific Custodians Pty Ltd – 31,585 Fully Paid Ordinary Shares</b> <b>MA Goodfellow – 13,000 Fully Paid Ordinary Shares and 100 NSS</b> <b>St Kentigern Trust – 430,434 Fully Paid Ordinary Shares and 19,727 NSS</b> <b>Sulkem Company Ltd – 129,787 Fully Paid Ordinary Shares</b> <b>Auckland Medical Research Foundation – 26,558 NSS</b> <b>Trustees of The Goodfellow Foundation – 33,854 Fully Paid Ordinary Shares and 1,338 NSS</b> <b>Henry Berry Corporation Limited – 420,861 Fully Paid Ordinary Shares 700 NSS</b>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<b>Shares issued under the Company's Dividend Reinvestment Plan.</b>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	<b>Not Applicable</b>
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.